Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2304402 Target Snapshot

cGMP-specific 3',5'-cyclic phosphodiesterase · SINGLE PROTEIN · Canis lupus familiaris

189Compounds
16Assays
2Approved Drugs
185.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt O77746. Use UniProt O77746 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt O77746 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats cGMP-specific 3',5'-cyclic phosphodiesterase as ChEMBL target CHEMBL2304402, mapped to UniProt O77746. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
cGMP-specific 3',5'-cyclic phosphodiesterase
SINGLE PROTEIN · Canis lupus familiaris
As of 2026-09-13
ChEMBL target ID
CHEMBL2304402
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
O77746
cGMP-specific 3',5'-cyclic phosphodiesterase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether cGMP-specific 3',5'-cyclic phosphodiesterase is the right protein anchor across sources, using UniProt O77746 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelcGMP-specific 3',5'-cyclic phosphodiesterase
UniProt AccessionO77746
Component TypeProtein
Sequence Length865 aa

cGMP-specific 3',5'-cyclic phosphodiesterase

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as cGMP-specific 3',5'-cyclic phosphodiesterase, mapped to UniProt O77746. Sequence length is 865 aa.

Mapped IDO77746
Review namecGMP-specific 3',5'-cyclic phosphodiesterase
OrganismCanis lupus familiaris
Clinical Profile

Clinical Phase Distribution

2
Approved
1
Phase II
1
Phase I
Assay Mix

Activity Type Distribution

IC50185.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3338455 10.28 IC50 0.053 Preclinical
CHEMBL3338445 9.89 IC50 0.13 Preclinical
CHEMBL3404016 9.68 IC50 0.21 Preclinical
CHEMBL538498 9.66 IC50 0.22 Preclinical
CHEMBL540031 9.66 IC50 0.22 Preclinical
CHEMBL540294 9.64 IC50 0.23 Preclinical
CHEMBL541822 9.54 IC50 0.29 Preclinical
CHEMBL77795 9.51 IC50 0.31 Preclinical
CHEMBL542409 9.42 IC50 0.38 Preclinical
CHEMBL3338448 9.42 IC50 0.38 Preclinical
Distribution

pChEMBL Value Distribution

11
5.0
16
5.5
12
6.0
10
6.5
14
7.0
22
7.5
18
8.0
21
8.5
13
9.0
7
9.5
pChEMBL
Approved Drugs

Approved Drugs

AVANAFIL
CHEMBL1963681
Approved 2011
SILDENAFIL
CHEMBL192
Approved 1998
Assay Landscape

Assay Landscape

16
Total Assays
152
Tested Compounds
1
Assay Types
Binding — 16 assays, 152 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 13 152 7.4
assay format 2 0
cell-based format 1 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine